

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/483,837 01/17/00 SHARMA

S 70025-9902-1

005179
PEACOCK MYERS AND ADAMS P C
P O BOX 26927
ALBUQUERQUE NM 87125-6927

HM12/1002

EXAMINER

CELSA, B

ART UNIT	PAPER NUMBER
----------	--------------

1627

14

DATE MAILED:

10/02/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

*file
copy*

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/483,837			

EXAMINER	
CELSA, BENNETT	
ART UNIT	PAPER NUMBER
1627	14
DATE MAILED:	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

NON RESPONSIVE LETTER: BONDAFIDE ATTEMPT

The communication filed on 5/9/2000 in paper no. 5 does not place the present application in full compliance with the amino acid/nucleotide sequence rules for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules: e.g. the specificaiton contains peptides which are not present in the submitted computer readable form (CRF) and do not contain sequence identifiers: see e.g. specification pages 5, 21, 42, 53, 70, 72, 73, 108 and 115.

Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be continued to be examined under 35 U.S.C. §§ 131 and 132.

Since the above-mentioned reply appears to be *bona fide* attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE (1) MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

General information regarding further correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Celsa whose telephone number is (703) 305-7556.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat (art unit 1627), can be reached at (703)308-0570.

Any inquiry of a general nature, or relating to the status of this application, should be directed to the Group receptionist whose telephone number is (703) 308-0196.
Bennett Celsa (art unit 1627)

September 30, 2001

BENNETT CELSA
PRIMARY EXAMINER



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirement for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821.
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached ~~marked up copy of the "Raw Sequence Listing."~~ *Bonfide ATTEMPT LETTER*
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7. Other: Specification contains sequences which are NOT IN CRF OR IF IN CRF - LACK SEQUENCE IDENTIFIERS
Applicant must provide: see: Pages 5(1.9-17), 21(1.6), 42(1.29), 53(1.14), 70(1.8), 72(1.16,22), 73(1.1), 108(11.19,26), 115(1.7)

- An ~~initial~~ or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An ~~initial~~ or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.